DAWN2™ is a global Novo Nordisk initiative conducted in collaboration with the IDF, IAPO, the Steno Diabetes Center and a range of other national, regional and global partners.

The DAWN2™ results highlight opportunities for improving diabetes care, education and community support by putting people with diabetes and their families centre stage. The DAWN2™ study will be used internationally and nationally to facilitate dialogue among patient organisations, healthcare professionals and other key stakeholders to develop action plans for improvement of the lives of people with diabetes. 

www.dawnstudy.com